Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01529281|
Recruitment Status : Completed
First Posted : February 8, 2012
Last Update Posted : February 8, 2012
|Condition or disease||Intervention/treatment||Phase|
|Exercise-induced Muscle Damage||Dietary Supplement: Branch Chain Amino Acid (BCAA) Dietary Supplement: Placebo - asparmate||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||September 2011|
Branched chain amino acid
Dietary Supplement: Branch Chain Amino Acid (BCAA)
Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with ~300 ml of water.
Placebo Comparator: Asparmate
Placebo control containing no protein or carbohydrate
Dietary Supplement: Placebo - asparmate
Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with ~300 ml of water.
- Maximal voluntary contraction [ Time Frame: pre exercise, 24 h, 48 h, 72 h, 96 h post-exercise ]Isometric MVC of the participants' dominant knee extensors was assessed using a strain gauge. MVCs were performed for 3 s with a 60 s rest between each repetition.
- Limb girths [ Time Frame: pre-exercise, 24h, 48h, 72h, 96h ]Mid-thigh and calf circumference was assessed as a measure of limb swelling using an anthropometric tape measure. Both measures were obtained with the participant in a standing position.
- Vertical jump [ Time Frame: pre-exercise, 24h, 48h, 72h, 96h ]Vertical jump (VJ) performance was assessed using the Vertec instrument. Participants performed a counter movement jump.
- Creatine kinase [ Time Frame: pre-exercise, 24h, 48h, 72h, 96h ]Plasma CK was determined from an earlobe capillary blood sample. The sample (30 microlitres) was analysed immediately using an automated, dry slide photospectrometer.
- Muscle soreness [ Time Frame: pre-exercise, 24h, 48h, 72h, 96h ]Muscle soreness - Participants were asked to perform and hold a squat (90° knee angle) whilst they rated their perceived muscle soreness on a 200 mm visual analogue scale. The scale consisted of a line from 0 mm (no pain) to 200 mm (unbearably painful).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01529281
|Principal Investigator:||Glyn Howatson, PhD||Northumbria University|